The effect of early prednisolone treatment on the generalization rate in ocular myasthenia gravis

European Journal of Neurology

Volumn 20, Issue 4, 2013, Pages 708-713

  Zach, H ^a   Cetin, H ^a   Hilger, E ^a   Paul, A ^a   Wuschitz, B ^a   Jung, R ^a   Auff, E ^a   Zimprich, F ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Early treatment; Generalized myasthenia gravis; Immunosuppressive therapy; Ocular myasthenia gravis; Prednisolone; Progression

Indexed keywords

CORTICOSTEROID; PREDNISOLONE; PYRIDOSTIGMINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; CONTROLLED STUDY; DRUG MEGADOSE; EARLY INTERVENTION; EYE DISEASE; FEMALE; FOLLOW UP; HUMAN; MALE; MEDICAL RECORD REVIEW; MYASTHENIA GRAVIS; OCULAR MYASTHENIA GRAVIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADULT; AGE OF ONSET; AGED; ANTI-INFLAMMATORY AGENTS; AUTOANTIBODIES; BLEPHAROPTOSIS; CHOLINESTERASE INHIBITORS; DISEASE PROGRESSION; EYE DISEASES; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MUSCLE WEAKNESS; MYASTHENIA GRAVIS; OCULOMOTOR MUSCLES; PREDNISOLONE; PYRIDOSTIGMINE BROMIDE; RECEPTORS, CHOLINERGIC; RETROSPECTIVE STUDIES; RISK ASSESSMENT;

EID: 84875054503     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/ene.12057     Document Type: Article

References (16)

1. Vincent A, Bowen J, Newsom-Davis J, McConville J. Seronegative generalised myasthenia gravis: clinical features, antibodies, and their targets. Lancet Neurol 2003; 2: 99-106.
2. Romi F, Gilhus N-E, Aarli JA. Myasthenia gravis: clinical, immunological, and therapeutic advances. Acta Neurol Scand 2005; 111: 134-141.
3. Oosterhuis HJ. The natural course of myasthenia gravis: a long term follow up study. J Neurol Neurosurg Psychiatry 1989; 52: 1121-1127.
4. Benatar M, Kaminski HJ. Quality Standards Subcommittee of the American Academy of Neurology. Evidence report: the medical treatment of ocular myasthenia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2007; 68: 2144-2149.
5. Grob D, Brunner N, Namba T, Pagala M. Lifetime course of myasthenia gravis. Muscle Nerve 2008; 37: 141-149.
6. Vanderlugt CL, Miller SD. Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat Rev Immunol 2002; 2: 85-95.
7. Feferman T, Im S-H, Fuchs S, Souroujon MC. Breakage of tolerance to hidden cytoplasmic epitopes of the acetylcholine receptor in experimental autoimmune myasthenia gravis. J Neuroimmunol 2003; 140: 153-158.
8. Bhanushali MJ, Wuu J, Benatar M. Treatment of ocular symptoms in myasthenia gravis. Neurology 2008; 71: 1335-1341.
9. Sommer N, Sigg B, Melms A, et al. Ocular myasthenia gravis: response to long-term immunosuppressive treatment. J Neurol Neurosurg Psychiatry 1997; 62: 156-162.
10. Kupersmith MJ, Latkany R, Homel P. Development of generalized disease at 2 years in patients with ocular myasthenia gravis. Arch Neurol 2003; 60: 243-248.
11. Papapetropoulos TH, Ellul J, Tsibri E. Development of generalized myasthenia gravis in patients with ocular myasthenia gravis. Arch Neurol 2003; 60: 1491-1492.
12. Mee J, Paine M, Byrne E, King J, Reardon K, O'Day J. Immunotherapy of ocular myasthenia gravis reduces conversion to generalized myasthenia gravis. J Neuroophthalmol 2003; 23: 251-255.
13. Monsul NT, Patwa HS, Knorr AM, Lesser RL, Goldstein JM. The effect of prednisone on the progression from ocular to generalized myasthenia gravis. J Neurol Sci 2004; 217: 131-133.
14. Hong Y-H, Kwon S-B, Kim B-J, et al. Prognosis of ocular myasthenia in Korea: a retrospective multicenter analysis of 202 patients. J Neurol Sci 2008; 273: 10-14.
15. Kupersmith MJ. Ocular myasthenia gravis: treatment successes and failures in patients with long-term follow-up. J Neurol 2009; 256: 1314-1320.
16. Allen JA, Scala S, Jones HR. Ocular myasthenia gravis in a senior population: diagnosis, therapy, and prognosis. Muscle Nerve 2010; 41: 379-384.